AbbVie Inc (NYSE: ABBV) has reported Q1 adjusted EPS of $2.46, down 22.2% Y/Y, in line with the consensus. Overall sales decreased 9.7% Y/Y (down 8.3% on an operational basis) to $12.23 billion, beating the consensus of $12.17 billion. The immunology portfolio generated $5.59 billion in sales, down 9% (-7.8% on an operational basis). Humira sales decreased 25.2% to $3.54 billion. In Q4, Humira sales increased 4.6% to $5.56 billion. Skyrizi sales reached $1.36 billion (+44.7% Y/Y), and Rinvoq jum